HJ-093
/ Chengdu Huajian Future Science and Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
HJ-093, a novel, orally bioavailable, and potent pan-RAS inhibitor, for the treatment of various RAS mutation-driven cancers [WITHDRAWN]
(AACR 2025)
- "HJ-093 is a potent pan-RAS inhibitor with the potential to be developed as a targeted therapy for various RAS mutation-driven cancers."
IO biomarker • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS
1 to 1
Of
1
Go to page
1